@article{3ad6ab3a908d4e44a4c379367e6f9635,
title = "Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination",
abstract = "Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination. Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay. Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender. Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.",
author = "Shen, {Ching Fen} and Fu, {Yi Chen} and Ho, {Tzong Shiann} and Chen, {Po Lin} and Lee, {Nan Yao} and Tsai, {Bo Yang} and Tsai, {Pei Jane} and Ko, {Wen Chien} and Liu, {Ching Chuan} and Cheng, {Chao Min} and Shieh, {Chi Chang}",
note = "Funding Information: We thank all participants for regular blood donations. We thank Shih-Wei Wang, Hui-Chin Shih, Hui-Feng Lee, Po-Ta Chen, Wei-Yun Huang for clinical recruitment and expert laboratory assistance. We thank the technical services provided by the Biosafety level 3 core laboratory of the National Core Facility for Biopharmaceuticals, National Science and Technology Council , Taiwan. We are grateful to Sheng-Hsiang Lin, Ph.D. for providing the statistical consulting services from the Biostatistics Consulting Center, Clinical Medicine Research Center, National Cheng Kung University Hospital . This study was supported by grants from Taiwan's National Science and Technology Council ( 111-2628-E-007-005-MY2 , 111-2314-B-006-085 , 111-2321-B-006-009 , 110-2923-B-006-001-MY4 ) and the Institute of Clinical Medicine, National Cheng Kung University Hospital , Tainan, Taiwan ( NCKUH-11202012 ). Funding Information: We thank all participants for regular blood donations. We thank Shih-Wei Wang, Hui-Chin Shih, Hui-Feng Lee, Po-Ta Chen, Wei-Yun Huang for clinical recruitment and expert laboratory assistance. We thank the technical services provided by the Biosafety level 3 core laboratory of the National Core Facility for Biopharmaceuticals, National Science and Technology Council, Taiwan. We are grateful to Sheng-Hsiang Lin, Ph.D. for providing the statistical consulting services from the Biostatistics Consulting Center, Clinical Medicine Research Center, National Cheng Kung University Hospital. This study was supported by grants from Taiwan's National Science and Technology Council (111-2628-E-007-005-MY2, 111-2314-B-006-085, 111-2321-B-006-009, 110-2923-B-006-001-MY4) and the Institute of Clinical Medicine, National Cheng Kung University Hospital, Tainan, Taiwan (NCKUH-11202012). Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
month = jun,
doi = "10.1016/j.clim.2023.109342",
language = "English",
volume = "251",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
}
